In 1971, J. Folkman published in the New England Journal of
Medicine a hypothesis that tumor growth is angiogenesis-dependent.
Folkman introduced the concept that tumors probably secrete
diffusible molecules that could stimulate the growth of new blood
vessels toward the tumor and that the resulting tumor
neovascularization could conceivably be prevented or interrupted by
angiogenesis inhibitors. Solid and haematological tumors consist of
an avascular and a subsequent vascular phase. Assuming that this
depends on the release of angiogenic factors, acquisition of
angiogenic capability can be seen as an expression of progression
from neoplastic transformation to tumor growth and metastasis.
Beginning in the 1980 s, the biopharmaceutical industry began
exploiting the field of antiangiogenesis for creating new
therapeutic compounds for modulating new blood vessels in tumor
growth. In 2004, Avastin (Bevacizumab), a humanized anti-VEGF
monoclonal antibody, was the first angiogenesis inhibitor approved
by the Food and Drug Administration for the treatment of colorectal
cancer. At present, it has been estimated that over 20,000 cancer
patients worldwide have received experimental form of
This book offers a historical account of the relevant
literature. It also emphasizes the crucial and paradigmatic role of
angiogenesis as a biological process and the significance of
antiangiogenic approach for the treatment of tumors."
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!